Does Tirzepatide Affect the Body's Ability to Recover from Low Blood Sugar?
Tirzepatide does not impair the body's hormonal response to low blood sugar in people with type 2 diabetes.
Quick Facts
What This Study Found
Tirzepatide 15 mg preserved counterregulatory hormone responses (including glucagon) during induced hypoglycemia, while lowering HbA1c by 1.5%.
Key Numbers
42 participants, crossover design. Tirzepatide 15 mg vs placebo for 12 weeks. HbA1c change: -1.5% vs +0.5%. Nadir PG: 44.5 vs 47.5 mg/dL. Glucagon response not different between groups.
How They Did This
Randomized, placebo-controlled crossover study with hypoglycemic clamp testing in 42 participants over 12 weeks.
Why This Research Matters
Confirming that tirzepatide doesn't blunt the body's defense against low blood sugar is critical for its safety in diabetes management.
The Bigger Picture
This safety data supports tirzepatide use in type 2 diabetes by showing it doesn't increase risk of severe hypoglycemia through impaired counterregulation.
What This Study Doesn't Tell Us
Only tested 15 mg dose. Crossover design requires adequate washout (8-10 weeks provided). Only type 2 diabetes patients studied.
Questions This Raises
- ?Are counterregulatory responses preserved at lower tirzepatide doses as well?
- ?Does this hold true in patients also taking insulin or sulfonylureas?
Trust & Context
- Key Stat:
- -1.5% HbA1c Tirzepatide reduced HbA1c by 1.5% while preserving counterregulatory hormone responses
- Evidence Grade:
- Well-designed randomized crossover study with clamp methodology — strong evidence for this specific safety question.
- Study Age:
- Published in 2025, providing important post-marketing safety data for tirzepatide.
- Original Title:
- Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.
- Published In:
- Frontiers in endocrinology, 16, 1627947 (2025)
- Authors:
- Pieber, Thomas R, Svehlikova, Eva, Urva, Shweta(4), Haupt, Axel, Zhou, Chunmei, Coskun, Tamer, Höller, Vera, Fluhr, Gabriele, Karanikas, Chrisanthi A, Milicevic, Zvonko, Pratt, Edward John
- Database ID:
- RPEP-13051
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does tirzepatide increase the risk of dangerous low blood sugar?
This study found that tirzepatide preserves the body's hormonal responses to low blood sugar, suggesting it does not increase hypoglycemia risk on its own.
What is a hypoglycemic clamp test?
A controlled procedure where blood sugar is deliberately lowered to measure how the body responds with counterregulatory hormones like glucagon.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13051APA
Pieber, Thomas R; Svehlikova, Eva; Urva, Shweta; Haupt, Axel; Zhou, Chunmei; Coskun, Tamer; Höller, Vera; Fluhr, Gabriele; Karanikas, Chrisanthi A; Milicevic, Zvonko; Pratt, Edward John. (2025). Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.. Frontiers in endocrinology, 16, 1627947. https://doi.org/10.3389/fendo.2025.1627947
MLA
Pieber, Thomas R, et al. "Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.." Frontiers in endocrinology, 2025. https://doi.org/10.3389/fendo.2025.1627947
RethinkPeptides
RethinkPeptides Research Database. "Counterregulatory response to hypoglycemia during a hypoglyc..." RPEP-13051. Retrieved from https://rethinkpeptides.com/research/pieber-2025-counterregulatory-response-to-hypoglycemia
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.